Shin Dong Wook, Bae Jaeman, Ha Johyun, Jung Kyu-Won
Supportive Care Center/Department of Family Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Department of Clinical Research Design & Evaluation, Samsung Advanced Institute for Health Science & Technology (SAIHST), Sungkyunkwan University, Seoul, South Korea.
Front Oncol. 2021 Apr 28;11:639839. doi: 10.3389/fonc.2021.639839. eCollection 2021.
Conditional relative survival (CRS) rates, which take into account changes in prognosis over time, are useful estimates for survivors and their clinicians as they make medical and personal decisions. We aimed to present the 5-year relative conditional survival probabilities of patients diagnosed with ovarian cancer from 1997-2016.
This nationwide retrospective cohort study used data from the Korean Central Cancer Registry. Patients diagnosed with ovarian cancer between 1997 and 2016 were included. CRS rates were calculated stratified by age at diagnosis, cancer stage, histology, treatment received, year of diagnosis, and social deprivation index.
The 5-year relative survival rate at the time of diagnosis was 61.1% for all cases. The probability of surviving an additional 5 years, conditioned on having already survived 1, 2, 3, 4, and 5 years after diagnosis was 65.0, 69.5, 74.6, 79.3, and 83.9%, respectively. Patients with poorer initial survival estimates (older, distant stage, serous histology) generally showed the largest increases in CRS over time. The probability of death was highest in the first year after diagnosis (11.8%), and the conditional probability of death in the 2, 3, 4, and 5 years declined to 9.4%, 7.9%, 6.1%, and 5.2%, respectively.
CRS rates for patients with ovarian cancer increased with each year they survived, but this did not reach the level of 'no excess mortality' even 5 years after diagnosis. The largest improvements in CRS were observed in patients with poorer initial prognoses. Our findings provide updated prognosis to ovarian cancer survivors and clinicians.
考虑到预后随时间的变化,条件相对生存率(CRS)对于幸存者及其临床医生在做出医疗和个人决策时是有用的估计值。我们旨在呈现1997年至2016年诊断为卵巢癌的患者的5年相对条件生存概率。
这项全国性回顾性队列研究使用了韩国中央癌症登记处的数据。纳入了1997年至2016年期间诊断为卵巢癌的患者。CRS率按诊断时的年龄、癌症分期、组织学、接受的治疗、诊断年份和社会剥夺指数进行分层计算。
所有病例诊断时的5年相对生存率为61.1%。在诊断后已存活1、2、3、4和5年的条件下,再存活5年的概率分别为65.0%、69.5%、74.6%、79.3%和83.9%。初始生存估计较差的患者(年龄较大、远处分期、浆液性组织学)随着时间的推移CRS增加通常最大。诊断后第一年的死亡概率最高(11.8%),而在第2、3、4和5年的条件死亡概率分别降至9.4%、7.9%、6.1%和5.2%。
卵巢癌患者的CRS率随着存活年份的增加而上升,但即使在诊断后5年也未达到“无额外死亡率”的水平。在初始预后较差的患者中观察到CRS的最大改善。我们的研究结果为卵巢癌幸存者和临床医生提供了最新的预后情况。